Exploring a novel outcome measure of symptom progression in knee osteoarthritis utilizing a large randomized trial.

Philip G Conaghan¹, Nathaniel Katz², David J Hunter³, Ali Guermazi⁴, Marc C Hochberg⁵, Kenneth Somberg⁶, Julia Clive⁶, Chris Knight⁶, Mary Johnson⁶, Luping Zhao⁶, Niti Goel⁷

¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, & NIHR Leeds Biomedical Research Centre, Leeds, UK. Electronic address: P.Conaghan@leeds.ac.uk.

²Tufts University, Department of Anesthesiology & Perioperative Medicine, Boston, MA, USA; Ein Sof Innovation, Boston, MA, USA.

³Sydney Musculoskeletal Health, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Rheumatology Department, Royal North Shore Hospital, St Leonards, Australia.

⁴Boston University School of Medicine, Radiology, Boston, MA, USA; VA Boston Healthcare System, Radiology, Boston, MA, USA.

⁵Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.

⁶Formation Bio, Inc., Research and Development, New York City, NY, USA.

⁷Formation Bio, Inc., Research and Development, New York City, NY, USA; Caduceus Biomedical Consulting, LLC, Durham, NC, USA; Duke University School of Medicine, Department of Medicine, Division of Rheumatology, Durham, NC, USA.

PubMed DOI

Abstract

OBJECTIVES: Explore a newly defined composite measure of symptom progression for knee osteoarthritis (KOA) in a large, randomized study of a potential disease-modifying osteoarthritis drug (DMOAD). DESIGN: Using longitudinal KOA studies, a potential composite endpoint of time to symptom progression was defined as the first occurrence of worsening of Western Ontario and McMaster Universities Osteo…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.